This is the authors' abstract. We don't add key points for this paper.
An immunosuppressive tumor microenvironment limits therapeutic efficacy and worsens prognosis in melanoma. Beyond T-cell abundance and function, effective tumor control also depends on whether T cells can access malignant cells within the tumor. Although emerging evidence supports that tumor vasculature facilitates immune evasion, the vascular mechanisms that govern intratumoral T-cell positioning remain poorly defined. Using RNA sequencing of endothelial cells isolated from tumor cores versus peripheries in a mouse melanoma model, we identified intercellular adhesion molecule 1 (ICAM-1) as a candidate regulator of T-cell localization. During tumor growth, T cells shifted from a balanced core-margin distribution to marked exclusion from the core, most prominently in T cell-inflamed tumors. This spatial redistribution -less evident in other immune subsets-coincided with high expression of lymphocyte function-associated antigen-1 (LFA-1) on T cells. In parallel, endothelial ICAM-1 became enriched at the tumor periphery, where vascular integrity was compromised, as evidenced by increased vascular leakage and reduced pericyte coverage. Functionally, ICAM-1 blockade restored intratumoral T-cell infiltration, enhanced effector activity, and significantly delayed the growth of immunogenic tumors. Moreover, ICAM-1 inhibition sensitized an immune-refractory tumor to anti-PD-1 checkpoint blockade. Together, these findings identify endothelial ICAM-1 as a vascular determinant of intratumoral T-cell positioning and highlight the ICAM-1/LFA-1 axis as a modifiable checkpoint to reverse T-cell retention at the tumor periphery, thereby enhancing antitumor immunity and immunotherapy efficacy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: